| Stage | UTI | % of rev | LINC | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $219M | 100.00% | $143M | 100.00% | UTI ×1.54 |
| Gross profit | $219M | 100.00% | $83M | 58.17% | UTI +41.8pp |
| Operating income | $3M | 1.48% | $3M | 2.32% | LINC +0.8pp |
| Pre-tax income | $3M | 1.42% | $2M | 1.59% | LINC +0.2pp |
| Net income | $2M | 1.04% | $2M | 1.37% | LINC +0.3pp |
| Stage | UTI | LINC | Gap · A − B |
|---|---|---|---|
| Revenue | $219M100.00% | $143M100.00% | UTI ×1.54 |
| Gross profit | 100.00%$219M | 58.17%$83M | UTI +41.8pp |
| Operating income | 1.48%$3M | 2.32%$3M | LINC +0.8pp |
| Pre-tax income | 1.42%$3M | 1.59%$2M | LINC +0.2pp |
| Net income |
| 1.04%$2M |
| 1.37%$2M |
| LINC +0.3pp |
No disclosed counterparties: LINC.
None